In vitro dissolution testing models of ocular implants for posterior segment drug delivery

• Published in: Drug Delivery and Translational Research
• Main Author: Adrianto M.F.; Annuryanti F.; Wilson C.G.; Sheshala R.; Thakur R.R.S.
• Format: Review
• Language: English
• Published: Springer 2022
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112306162&doi=10.1007%2fs13346-021-01043-z&partnerID=40&md5=a064e4a0cf6a1c4e1ec62d166cb2e4da

The delivery of drugs to the posterior segment of the eye remains a tremendously difficult task. Prolonged treatment in conventional intravitreal therapy requires injections that are administered frequently due to the rapid clearance of the drug molecules. As an alternative, intraocular implants can offer drug release for long-term therapy. However, one of the several challenges in developing intraocular implants is selecting an appropriate in vitro dissolution testing model. In order to determine the efficacy of ocular implants in drug release, multiple in vitro test models were emerging. While these in vitro models may be used to analyse drug release profiles, the findings may not predict in vivo retinal drug exposure as this is influenced by metabolic and physiological factors. This review considers various types of in vitro test methods used to test drug release of ocular implants. Importantly, it discusses the challenges and factors that must be considered in the development and testing of the implants in an in vitro setup. Graphical abstract: [Figure not available: see fulltext.] © 2021, The Author(s).